ArticleVaccines2023

Survivin (BIRC5) Peptide Vaccine in the 4T1 Murine Mammary Tumor Model: A Potential Neoadjuvant T Cell Immunotherapy for Triple Negative Breast Cancer: A Preliminary Study.

Scott R Burkholz et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.